1.
Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis E Fayad, Nancy L. Bartlett, Douglas E. Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham H. Wilson, Andre Goy, Anas Younes, Hun Ju Lee. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica 2019;104(2):e65-e67; https://doi.org/10.3324/haematol.2018.199844.